Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1 - IgV

Cytotherapy

Volumn 10, Issue 7, 2008, Pages 711-719

  Zhang, C ^a,b   Wu, S ^a,b   Xue, X ^a,b   Li, M ^a,b   Qin, X ^a,b   Li, W ^a,b   Han, W ^a,b   Zhang, Y ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b State Key Laboratory of Cancer Biology   (China)

Author keywords

Anti tumor immunotherapy; IgV domain of programmed death 1 (PD 1); Recombinant protein

Indexed keywords

CD28 ANTIGEN; CYCLOPHOSPHAMIDE; PROGRAMMED DEATH 1 ANTIGEN; PROGRAMMED DEATH 1 ANTIGEN IMMUNOGLOBULIN V; PROGRAMMED DEATH 1 LIGAND; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; LOW DRUG DOSE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME;

EID: 56049087551     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240802320237     Document Type: Article

References (17)

1. Ohigashi, Y., Sho, M. Yamada, Y. et al. (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res, 11, pp. 2947-2953.
2. Nakae, S., Suto, H. Iikura, M. et al. (2006) Mast cells enhance T cell activation: Importance of mast cell costimulatory molecules and secreted TNF. J Immunol, 176, pp. 2238-2248.
3. Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J, 11, pp. 3887-3895.
4. Nishimura, H. and Honjo, T. (2001) PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol, 22, pp. 265-268.
5. Dong, H., Zhu, G., Tamada, K. and Chen, L. (1999) B7-H1, a third member of the B7 family, co-stimulates T cell proliferation and interleukin-10 secretion. Nat Med, 5, pp. 1365-1369.
6. Tseng, SY, Otsuji, M. Gorski, K. et al. (2001) B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med, 193, pp. 839-846.
7. Latchman, Y., Wood, CR Chernova, T. et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol, 2, pp. 261-268.
8. Yonungnak, P., Kozono, Y. Kozono, H. et al. (2003) Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun, 307, pp. 672-677.
9. Loke, P. and Allison, JP. (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sic USA, 100, pp. 5336-5341.
10. Nishimura, H., Nose, M. Hiai, H. et al. (1999) Development of lupus-like autoimmune disease by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11, pp. 142-151.
11. Iwai, Y., Ishida, M. Tanaka, Y. et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immuno-therapy by PD-L1 blockade. Proc Natl Acad Sci USA, 99, pp. 12293-12297.
12. Hirano, F., Kaneko, K. Tamura, H. et al. (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res, 65, pp. 1089-1096.
13. Dong, H., Strome, SE Salomao, DR et al. (2002) Tumor-associated B7-H1 promotes T cell apoptosis: A potential mechanism of immune evasion. Nat Med, 8, pp. 793-800.
14. + suppressor T cells: more questions than answers. Nat Rev Immunol, 2, pp. 389-400.
15. McCarter, MD, Baumgartner, J. Escobar, GA et al. (2007) Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol, 14, pp. 2854-2860.
16. Sharma, MD, Baban, B. Chandler, P. et al. (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest, 117, pp. 2570-2582.
17. Zhang, X., Schwartz, JC Guo, X. et al. (2004) Structural and functional analysis of the costimulatory receptor programmed death-1[J]. Immunity, 20, pp. 337-347.